Dabigatran etexilate Completed Phase 1 Trials for Scleroderma / Interstitial Lung Disease (ILD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02426229Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma